Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2013-10-10

Clinical Trial Update: Nebulized Albuterol for Congestive Heart Failure Exacerbation [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating nebulized albuterol for congestive heart failure exacerbation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Albuterol (nebulized) (albuterol)

Snippet

Sponsor: University of California, San Francisco | Conditions: Congestive Heart Failure | Phase 2, Phase 3 | Status: WITHDRAWN